{"filing":{"accession_number":"0001640334-26-001485","cik":"0001697884","ticker":null,"company_name":"VITASPRING BIOMEDICAL CO. LTD.","form":"8-K","filing_date":"2026-09-10","report_date":"2026-09-07","primary_document":"vsbc_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1697884/000164033426001485/vsbc_8k.htm"},"events":[{"id":32604,"run_id":29964,"accession_number":"0001640334-26-001485","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Dr. Ssu-Chuan Lai resigned effective September 7, 2026, from her positions as Chairperson, CEO, President, CFO, and Secretary—a complete departure from all executive and board roles. While the filing also discloses the appointment of her successors (Chen and Shih), the primary and most salient event is the departure of the company's founder and top executive. The resignation of a CEO and board chair is material to investors assessing leadership continuity and governance.","company_name":"VITASPRING BIOMEDICAL CO. LTD.","ticker":null,"filing_date":"2026-09-10","form":"8-K","submitted_at":null,"items":[{"id":35816,"accession_number":"0001640334-26-001485","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Dr. Ssu-Chuan Lai resigned effective September 7, 2026, from her positions as Chairperson, CEO, President, CFO, and Secretary—a complete departure from all executive and board roles. While the filing also discloses the appointment of her successors (Chen and Shih), the primary and most salient event is the departure of the company's founder and top executive. The resignation of a CEO and board chair is material to investors assessing leadership continuity and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T17:23:36.764367+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35816,"accession_number":"0001640334-26-001485","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Dr. Ssu-Chuan Lai resigned effective September 7, 2026, from her positions as Chairperson, CEO, President, CFO, and Secretary—a complete departure from all executive and board roles. While the filing also discloses the appointment of her successors (Chen and Shih), the primary and most salient event is the departure of the company's founder and top executive. The resignation of a CEO and board chair is material to investors assessing leadership continuity and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T17:23:36.764367+00:00","company_name":"VITASPRING BIOMEDICAL CO. LTD.","ticker":null,"filing_date":"2026-09-10"}]}